Drug intelligence / Profile preview

p300 HAT inhibitor

Development stage
Preclinical
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

p300 HAT inhibitors are a class of small molecules designed to inhibit the histone acetyltransferase (HAT) activity of the p300 (EP300) protein and its closely related paralog, CBP (CREB-binding protein). These proteins function as transcriptional co-activators that modify chromatin structure by acetylating lysine residues on histones (notably H3K18 and H3K27) and various non-histone proteins, such as p53, GATA4, and NF-κB. By blocking this enzymatic activity, p300 HAT inhibitors can downregulate the expression of key oncogenic drivers like c-Myc and HIF-1α. This class of epigenetic modulators is being investigated for the treatment of various cancers, including multiple myeloma, prostate cancer, and glioblastoma, as well as for their potential to reverse chemoresistance and treat cardiovascular conditions like hypertension-induced cardiac hypertrophy.

Other names
p300 HAT inhibitorp-300 HAT inhibitorp 300 HAT inhibitorp300 inhibitorsp-300 inhibitorsp 300 inhibitorsEP300 inhibitorsEP-300 inhibitorsEP 300 inhibitorsp300/CBP HAT inhibitorsHistone acetyltransferase p300 inhibitors
02

Targets

BRD4 (Bromodomain-containing protein 4)CREB-binding protein histone acetyltransferase domainCREBBP BD (Creb-binding protein bromodomain)EP300 (Histone acetyltransferase p300)CREBBP (CREB-binding protein)

Beyond the preview

Go deeper on p300 HAT inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on p300 HAT inhibitor.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call